Key points are not available for this paper at this time.
You have accessJournal of UrologyProstate Cancer: Detection 19%), 2 (n=53; 6%), 3 (n=21; 3%), 4 (n=13; 2%), and 5-10 (n=17; 2%) PNI foci were present in other cases. In the entire cohort, we confirmed a significantly higher risk of biochemical recurrence in patients with PNI (vs. no PNI; p<0.001) or multifocal PNI (vs. single PNI; p<0.001), while the difference in recurrence-free survival between 0 vs. 1 PIN was not statistically significant (p=0.106) (see Figure 1 and Table 1). In subgroup analysis, marginal and significant differences in the risk of recurrence between single vs. multifocal PNI were seen in patients with GG1 cancer (p=0.056) and GG2 (p<0.001) or GG3 (p<0.001) cancer, respectively, but not in those with GG4 (p=0.214) or GG5 (p=0.484) cancer. By contrast, the prognostic impact of the presence (vs. absence) of PNI was observed in patients with GG3 (p<0.001) or GG4 (p=0.003) cancer, but not in those with GG1 (p=0.870) or GG2 (p=0.307) cancer. CONCLUSIONS: These results suggest that PNI quantification on biopsy provides useful information for more accurate risk stratification particularly in patients with GG2-3 prostate cancer. Meanwhile, the presence of PNI may not necessarily be a strong prognosticator (e.g. GG1-2 cancer). Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1195 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Yuki Teramoto More articles by this author Ying Wang More articles by this author Hiroshi Miyamoto More articles by this author Expand All Advertisement PDF downloadLoading ...
Teramoto et al. (Mon,) studied this question.